A66 | A murine viral outgrowth assay to detect HIV in patients with undetectable viral loads | MOAA0101 | Oral Abstract |
A36 | Virologic and immunologic correlates of viral control post-ART interruption in SIV-infected rhesus macaques | MOAA0102 | Oral Abstract |
A35 | Anti-HIV antibody responses reflect the quantifiable HIV reservoir size | MOAA0103 | Oral Abstract |
A33 | Trancriptomics and metabolomics identify inflammatory profiles that segregate subjects with high and low inducible HIV reservoir | MOAA0104 | Oral Abstract |
A36 | HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally-infected child | MOAA0105LB | Oral Abstract |
A35 | Time associated changes in cell-associated HIV RNA in HIV-infected subjects on suppressive antiretroviral therapy - implications for clinical trials of cure interventions | MOAA0106LB | Oral Abstract |
A52 | Treatment with anti-α4β7 integrin antibody reduces virus-mediated gastrointestinal pathology by targeting distinct mucosal tissues | MOAA0202 | Oral Abstract |
A30 | Oral microbiome in HIV-infected women: aging, disease progression and opportunistic infections increase the pathogenic profile | MOAA0203 | Oral Abstract |
A24 | Serum-derived bovine immunoglobulin isolate increases peripheral and mucosal CD4 T cell count in patients with HIV enteropathy | MOAA0204 | Oral Abstract |
A54 | HIV-exposure, gut microbiome, and vaccine responses in South African infants | MOAA0205 | Oral Abstract |
A13 | SIV-induced translocation of bacterial products in the liver mobilizes myeloid dendritic and natural killer cells associated with liver damage | MOAA0206LB | Oral Abstract |
A67 | Low frequency HIV drug resistance in Ugandan patients failing ART with susceptible HIV Sanger genotyping | MOLBPE01 | Poster Exhibition |
A2 | Within-host evolution of X4 HIV-1 in a rare transmission pair revealed by phylogenetic reconstruction of deep-sequence data | MOPDA0101 | Poster Discussion Abstract |
A40 | Genetic ancestry component proportions are correlated with HIV disease progression | MOPDA0102 | Poster Discussion Abstract |
A33 | Dasatinib preserves SAMHD1 antiviral activity in CD4+ T cells treated with IL-7 | MOPDA0103 | Poster Discussion Abstract |
A51 | HIV-specific latency reversing therapies that exploit novel pathways for suboptimal Tat protein expression | MOPDA0104 | Poster Discussion Abstract |
A51 | HIV rebound and meningoencephalitis following ART interruption after allogeneic hematopoietic stem cell transplant: an investigation of the source of HIV rebound | MOPDA0105 | Poster Discussion Abstract |
A35 | Assay to measure the latent reservoir of replication-competent HIV-1 in suppressed patients based on ultra deep sequencing | MOPDA0106LB | Poster Discussion Abstract |
A17 | Monoclonal antibodies using IgG-V regions from cows vaccinated with HIV gp140 require cysteine and tryptophan for high affinity Env trimer-specific binding | MOPEA001 | Poster Exhibition |
A18 | Early initiation of treatment in primary HIV infection leads to temporary preservation of the B-cell compartment | MOPEA002 | Poster Exhibition |
A18 | Numerical and phenotypic B-cell abnormalities and vaccine responses in HIV-exposed uninfected (HEU) children | MOPEA003 | Poster Exhibition |
A19 | Control of HIV-1 by cytotoxic T cells specific for multiple conserved epitopes | MOPEA004 | Poster Exhibition |
A20 | Bacterial vaginosis is associated with loss of gamma delta T cells in the female reproductive tract | MOPEA005 | Poster Exhibition |
A20 | Effects of quadruple first-line ART on mucosal immunity and HIV persistence | MOPEA006 | Poster Exhibition |
A20 | Hormonal contraception and cervical immunity before and after HIV acquisition | MOPEA007 | Poster Exhibition |
A21 | Reporter assay to measure HIV-1 Nef-mediated evasion from T cells | MOPEA008 | Poster Exhibition |
A21 | Nef and Vpu accessory proteins from primary HIV-1 isolates protect infected cells from ADCC | MOPEA009 | Poster Exhibition |
A21 | Novel approach to identify new ADCC-mediating antibodies targeting the HIV-1 envelope | MOPEA010 | Poster Exhibition |
A21 | Identification of HLA-associated polymorphisms in a cohort of HIV-1 subtype A/E infection | MOPEA011 | Poster Exhibition |
A36 | Profound alterations in cholesterol metabolism restrict HIV-1 trans infection of CD4 T cells in nonprogressors | MOPEA013 | Poster Exhibition |
A37 | Characterization of anti-gp41 antibodies eliciting viral neutralization and protecting against CD4 depletion in long-term non-progressors | MOPEA014 | Poster Exhibition |
A37 | CD40L-induced tunneling nanotube networks facilitate proinflammatory dendritic cell-mediated HIV-1 trans-infection of CD4+ T cells | MOPEA015 | Poster Exhibition |
A38 | Plasma and PBMC miRNA profile in sexually HIV-exposed seronegative individuals | MOPEA016 | Poster Exhibition |
A38 | Immune activation is present in HIV-1 exposed seronegative individuals (HESN) and is indipendent from microbial translocation | MOPEA017 | Poster Exhibition |
A39 | Association of the presence of HIV-1 broadly neutralizing antibodies during pregnancy and prevention of mother to child transmission at delivery | MOPEA018 | Poster Exhibition |
A39 | Neutralizing antibody response in chronically HIV-1 infected ART naïve children from India: a follow-up study | MOPEA019 | Poster Exhibition |
A39 | Identification of the structural determinants for the selective anti-HIV-1 activity of the all-β alternative conformer of the γ-chemokine XCL1/lymphotactin | MOPEA020 | Poster Exhibition |
A42 | Effect of rectal gonorrhea and chlamydia on cytokine expression and HIV viral load in the rectum | MOPEA021 | Poster Exhibition |
A42 | CD161-expression on CD4+ T cells is enriched in the female genital tract and identifies a subset of activated cells rather than Th17 commitment as in blood | MOPEA022 | Poster Exhibition |
A42 | HIV-1 Nef controls cellular invasion through differential modulation of host proteins | MOPEA023 | Poster Exhibition |
A45 | Galectin-3 promotes HIV-1 cell-to-cell transmission via up-regulating GM1 ganglioside in lipid raft of CD4+ T cells | MOPEA024 | Poster Exhibition |
A46 | Early antiretroviral treatment (ART) fails to achieve sustained HIV viral remission but limits viral diversity | MOPEA025 | Poster Exhibition |
A54 | Strong functional constraint at residues in HIV-1 Gag are predicted by measures of evolutionary rather than population-level genetic conservation | MOPEA026 | Poster Exhibition |
A54 | Effect of losartan on lymphoid tissue fibrosis and inflammation in virologically suppressed HIV patients after 48 weeks | MOPEA027 | Poster Exhibition |
A55 | Modulation of binding antibody responses to trimeric gp145 and gp41 HIV-1 envelope proteins by utilizing different adjuvants and delivery platforms as a prime-boost strategy | MOPEA028 | Poster Exhibition |
A56 | pVLP: a new DNA vaccine strategy for HIV | MOPEA029 | Poster Exhibition |
A56 | Deletion of immunomodulatory A44L, A46R and C12L viral genes from Modified Vaccinia Ankara (MVA) genome: effect on its immunogenicity | MOPEA030 | Poster Exhibition |
A56 | Generating an anti-HIV vaccine using lipid nanoparticle-encapsulated nucleoside-modified mRNA encoding envelope | MOPEA031 | Poster Exhibition |
A56 | Immunological characterization of an HIV vaccine comprised of Gag and dgp41 virus-like particles produced both in plants and by live Vaccinia virus vectors | MOPEA032 | Poster Exhibition |
A57 | Monocyte-derived DC electroporated with mRNAs encoding both specific HIV antigens and DC adjuvants are able to improve T cell functionality | MOPEA033 | Poster Exhibition |
A57 | Therapeutic conserved elements (CE) DNA vaccine increases T cell responses against highly conserved viral sequences in the setting of pre-existing immunodominant responses induced by chronic viral infection | MOPEA034 | Poster Exhibition |
A57 | Immune response to sequences surrounding the 12 protease cleavage sites generated during ARV treatment improved CD4 counts of SIVmac251 infected rhesus monkeys | MOPEA035 | Poster Exhibition |
A57 | Safety and immunogenicity of ChAd.HIVconsv and MVA.HIVconsv therapeutic vaccines in a cohort of early treated HIV-1 infected individuals | MOPEA036 | Poster Exhibition |
A57 | Development of a latency reversing activator vaccine (ACT-VEC) platform for HIV-1 cure therapy | MOPEA037 | Poster Exhibition |
A57 | VAC-3S immunotherapeutic HIV vaccine combined with ART is immunogenic and safe. Phase II initial analysis of the IPROTECT1 multicenter European study | MOPEA038 | Poster Exhibition |
A57 | Broadly specific, cytolytic T cell responses and lower inflammatory responses correlate with durable viral remission following therapuetic DNA vaccination in SIV-infected macaques | MOPEA039 | Poster Exhibition |
A58 | Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda | MOPEA040 | Poster Exhibition |
A60 | Stability of the NS3 Q80K polymorphism over time within HCV genotype 1a infected patients | MOPEA041 | Poster Exhibition |
A60 | Discovery of a novel class of naturally occurring indirect-acting antiviral agents against both HIV-1 and hepatitis C virus infection | MOPEA042 | Poster Exhibition |
A65 | Changes in concentrations of circulating calprotectin and S100A9 in successfully treated HIV-1 patients over time | MOPEA043 | Poster Exhibition |
A65 | External quality assurance improves both domestic and international laboratory performance for peripheral blood mononuclear cell cryopreservation | MOPEA044 | Poster Exhibition |
A67 | Applying TRIP technology to visualise latent HIV-1 integrations on chromosome landscapes | MOPEA045 | Poster Exhibition |
A67 | Determination of integrase inhibitor resistance using a novel HIV phenotype assay | MOPEA046 | Poster Exhibition |
A70 | SIVagm from vervet African green monkeys can utilize non-CCR5 entry pathways in vitro and ex vivo | MOPEA047 | Poster Exhibition |
A71 | Probing and characterizing resistance to integrase inhibitors using simian immunodeficiency virus 239 | MOPEA048 | Poster Exhibition |
A18 | HIV-induced abnormalities of the B-cell compartment persist in patients on long-term ART and may reflect a state of terminal B-cell exhaustion | PUB001 | Publication Only |
A35 | Flow-based differentiation between latently HIV-1-infected single cells expressing Gag mRNA alone or in conjunction with Gag protein following latency reversal | PUB002 | Publication Only |
A35 | Improved assays to measure the inducible latent HIV reservoir | PUB003 | Publication Only |
A42 | The tip of the iceberg: impact of asymptomatic STI's on immune cells in the male foreskin | PUB004 | Publication Only |
A51 | Reversal of HIV-1 latency by activation of patient-derived CD4+T-cells results in clonal expansion and sustained production of infectious virus from a subset of cells | PUB005 | Publication Only |
A2 | Phylogenetically estimated HIV diversification rates reveal prevention of HIV-1 by antiretroviral therapy | TUAA0101 | Oral Abstract |
A45 | Phenotypic properties influencing HIV-1 transmission fitness | TUAA0102 | Oral Abstract |
A1 | Population-level spread of immune-driven mutations in HIV-1 polymerase during the North American epidemic | TUAA0103 | Oral Abstract |
A6 | Primary resistance against dolutegravir decreases HIV integration | TUAA0104 | Oral Abstract |
A6 | HIV-1 integrase variants retarget proviral integration and are associated with disease progression | TUAA0105 | Oral Abstract |
A40 | HIV-1 specific IgG antibody levels correlate with presence of a specific HLA class II allele to impact acquisition and vaccine efficacy | TUAA0106LB | Oral Abstract |
A51 | Zinc finger nuclease gene editing for functional cure in a nonhuman primate model of HIV/AIDS | TUAA0202 | Oral Abstract |
A71 | Crispr/Cas9 gene editing eradicates latent and protects cells against new HIV-1 infection | TUAA0203 | Oral Abstract |
A34 | Investigating the role of the immune checkpoint receptor TIGIT in T cells during HIV disease progression and as a target for immune restoration | TUAA0204LB | Oral Abstract |
A33 | Estrogen blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirs | TUAA0205LB | Oral Abstract |
A51 | Novel activators of latent HIV-1 from natural products | TULBPE02 | Poster Exhibition |
A52 | CD4 mimetics sensitize HIV-1-infected cells to ADCC | TULBPE03 | Poster Exhibition |
A52 | Enhancement of microbiota in healthy macaques results in robust beneficial modulation of mucosal and systemic immune function | TULBPE04 | Poster Exhibition |
A29 | Association between CSF and peripheral markers of immune-activation/inflammation and elevated intrathecal HIV-RNA levels in a cohort of HIV-infected antiretroviral naïve individuals | TUPDA0101 | Poster Discussion Abstract |
A13 | Receptor mediated endocytosis directs subcellular trafficking and TLR signaling of HIV-1 in plasmacytoid dendritic cells | TUPDA0102 | Poster Discussion Abstract |
A11 | HIV-1 Vpu exploits the crosstalk between BST2 and the ILT7 receptor to inhibit innate sensing of infected T cells by plasmacytoid dendritic cells | TUPDA0103 | Poster Discussion Abstract |
A8 | HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the promoter | TUPDA0104 | Poster Discussion Abstract |
A11 | Polymorphisms in TRIM22 are associated with HIV-2 acquisition and disease progression | TUPDA0105 | Poster Discussion Abstract |
A26 | The negative checkpoint receptor TIGIT marks exhausted T cells during SIV infection and correlates with SIV disease progression | TUPDA0106LB | Poster Discussion Abstract |
A1 | Phylogenetic estimation of the temporal spread of hepatitis C genotype 1a in North America | TUPEA049 | Poster Exhibition |
A1 | Origin and evolutionary history of HIV-2 in Cuba | TUPEA050 | Poster Exhibition |
A2 | Molecular epidemiology of clinical HIV-1 pol sequences isolated between January 2009 and July 2013 in Cuba | TUPEA051 | Poster Exhibition |
A2 | The Local Dissemination Impact of the HIV-1 env LDI tripeptide α4β7 binding motif | TUPEA052 | Poster Exhibition |
A2 | Evolution of the HIV-1 envelope gene during suppressive cART | TUPEA053 | Poster Exhibition |
A2 | Multiplexed highly-accurate next-generation sequencing of mixtures of full-length HIV genome variants | TUPEA054 | Poster Exhibition |
A2 | HIV-1 circular recombinant CRF02-AG: rapid spread in Russia and neighboring countries | TUPEA055 | Poster Exhibition |
A2 | A new framework for reconstructing epidemic dynamics from virus sequences: model validation and application to the HIV CRF07-BC epidemic in China | TUPEA056 | Poster Exhibition |
A2 | Prevalence, evolutionary dynamics and transmission pattern of HCV, HIV-1 and HPgV among injecting drug users | TUPEA057 | Poster Exhibition |
A2 | Identification and genetic characterisation of a novel HIV-1 circulating recombinant lineage (CRF74_01B) among people who inject drugs in Malaysia | TUPEA058 | Poster Exhibition |
A2 | Kive: a framework for version control of bioinformatic pipelines and data, and its application to HIV resistance genotyping | TUPEA059 | Poster Exhibition |
A2 | Newly diagnosed HIV-1 infections in Spain frequently group in clusters of subtype B and non-subtype B genetic forms | TUPEA060 | Poster Exhibition |
A2 | Prevalence of defective HIV-1 genome in HIV-infected patients on long-term cART and correlation with characteristics of patients | TUPEA061 | Poster Exhibition |
A2 | Full-length ultra-deep sequencing of HIV-1 transmission partners reveals the impact of intra-host evolution on immune control | TUPEA062 | Poster Exhibition |
A3 | Consequences of HLA-B*13-associated escape mutations on HIV-1 replication and Nef protein function | TUPEA063 | Poster Exhibition |
A3 | Drug susceptibility and viral fitness of integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations in combination | TUPEA064 | Poster Exhibition |
A3 | SIV CTL escape mutations resulting in loss of viral fitness can be maintained after transmission into MHC-I-mismatched hosts | TUPEA065 | Poster Exhibition |
A4 | Transmission dynamics of local networks of transmitted resistance to NNRTIs suggest an increasing incidence over time in Greece: the added value of molecular epidemiology to public health | TUPEA066 | Poster Exhibition |
A4 | HIV resistance pathways support the use of lamivudine (3TC) and dolutegravir (DTG) in combination | TUPEA067 | Poster Exhibition |
A4 | Evolution of HIV-1 integrase following selection of R263K with further dolutegravir treatment: a case report from the P1093 study | TUPEA068 | Poster Exhibition |
A40 | Degradation of HIV-1 Nef by ubiquitin (Ub) specific protease 15 (USP15) | TUPEA069 | Poster Exhibition |
A40 | Independent association of host immunogenetic factors with vertical HIV transmission | TUPEA070 | Poster Exhibition |
A40 | Expression analysis of α4 integrin and related genetic polymorphisms in HIV acquisition and disease progression of infected individuals | TUPEA071 | Poster Exhibition |
A40 | Human leukocyte antigen (HLA) typing and novel allele description by next generation sequencing in HIV-1-infected individuals from Southern Brazil | TUPEA072 | Poster Exhibition |
A40 | Absence of an association between mannose binding lectin deficiency and HIV-1 disease progression in an adult population in Zimbabwe | TUPEA073 | Poster Exhibition |
A41 | Global mapping of HIV-1 and host-cells molecular interactions | TUPEA074 | Poster Exhibition |
A47 | TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human PBMCs | TUPEA075 | Poster Exhibition |
A47 | A novel acylguanidine-based inhibitor of HIV-1 egress | TUPEA076 | Poster Exhibition |
A47 | Novel CD4-mimetic small molecules show enhancement of the neutralization activity of anti-cryptic V3 neutralizing antibody, KD-247 | TUPEA077 | Poster Exhibition |
A47 | BMS-955176: characterization of a 2nd-generation HIV-1 maturation inhibitor | TUPEA078 | Poster Exhibition |
A47 | Small molecule activator of protein phosphatase 1 (SMAPP1) activates latent HIV-1 provirus | TUPEA079 | Poster Exhibition |
A47 | Discovery and anti-HIV-1 activity of a new class of diheteroarylamide-type anti-HIV-1 agents acting on HIV-1 alternative splicing | TUPEA080 | Poster Exhibition |
A47 | Discovery of novel HIV-1 inhibitors from natural products | TUPEA081 | Poster Exhibition |
A47 | Development of efficient parallel synthesis strategies for the generation of compound libraries of anti-HIV agents that alter HIV alternative splicing | TUPEA082 | Poster Exhibition |
A49 | Antiviral activity of 5-Hydroxytyrosol, a microbicidal candidate against HIV-1 transmission | TUPEA083 | Poster Exhibition |
A49 | Protection from HIV-1 infection by S-layer mediated display of anti-HIV proteins on Caulobacter crescentus | TUPEA084 | Poster Exhibition |
A51 | MG1 and VSVΔ51 viruses target and kill latently HIV-infected myeloid cells | TUPEA085 | Poster Exhibition |
A51 | Risk of virologic rebound in HIV-infected patients on HAART with very low-level viraemia | TUPEA086 | Poster Exhibition |
A51 | Minimal HIV-1 Gag epitope presentation in a T cell line during reactivation | TUPEA087 | Poster Exhibition |
A51 | Vorinostat, panobinostat and romidepsin nonselectively activate transcription from quiescent HIV-1 proviruses in HIV-infected individuals on long-term suppressive antiretroviral therapy | TUPEA088 | Poster Exhibition |
A51 | Combinatorial CRISPR/Cas9 approaches targeting different steps in the HIV life cycle efficiently limits viral reactivation and halts viral replication | TUPEA089 | Poster Exhibition |
A51 | Universal Tre-recombinase (uTre) specifically targets the majority of primary HIV-1 isolates | TUPEA090 | Poster Exhibition |
A51 | Polyvalent immune responses correlate with lower number of HIV-infected CD4 T cells in chronically infected subjects treated with autologous RNA pulsed DC therapy | TUPEA091 | Poster Exhibition |
A51 | Latency reversal Agent (LRA) romidepsin reactivates latent virus in two rhesus macaque (RM) models of controlled SIV infection in the absence of antiretroviral therapy (ART) | TUPEA092 | Poster Exhibition |
A51 | Robust HIV-specific T cells in post-treatment controllers from the VISCONTI cohort | TUPEA093 | Poster Exhibition |
A51 | Nef inhibition for enhanced NK cell killing of cells expressing reactivated HIV-1 | TUPEA094 | Poster Exhibition |
A51 | Emergence of infectious treatment-resistant HIV after provirus-directed endonuclease therapy | TUPEA095 | Poster Exhibition |
A52 | Selection and evaluation of specific single chain antibodies against gp41 of HIV | TUPEA096 | Poster Exhibition |
A52 | Antibody-dependent cellular cytotoxicity against cells latently infected with HIV | TUPEA097 | Poster Exhibition |
A52 | Potent and broad neutralizing activity of small antibody fragments targeting CD4i (CD4-induced) epitope | TUPEA098 | Poster Exhibition |
A52 | A novel TLR-9 agonist (MGN1703) activates NK-cells and enhances NK-cell mediated viral killing of HIV-1 infected CD4+ T cells ex vivo | TUPEA099 | Poster Exhibition |
A17 | Comparison of HIV-1 envelope specific IgA and IgG antiviral ability to prevent HIV-1 infection: additive, inhibitory and synergistic effects | WEAA0101 | Oral Abstract |
A17 | Anti-V3/glycan and anti-MPER neutralizing antibodies, but not anti-V2/glycan-site antibodies are strongly associated with higher anti-HIV-1 neutralization breadth and potency | WEAA0102 | Oral Abstract |
A40 | Impact of HLA-B*35 alleles on HIV disease outcome in Mexico and Central America | WEAA0103 | Oral Abstract |
A51 | Type-1 programmed dendritic cells induce primary CTL capable of effectively targeting the HIV-1 reservoir | WEAA0104 | Oral Abstract |
A34 | Molecular determinants of HIV-1 permissiveness and persistence in gut-homing CD4+ T cells expressing the Th17 marker CCR6 | WEAA0105 | Oral Abstract |
A56 | The potential of attenuated Mycobacterium tuberculosis or BCG vaccines to enhance oral SIV acquisition in infant macaques | WEAA0106LB | Oral Abstract |
A23 | CD4 T cell reconstitution following cART is immediate as is CD4+T cell depletion following treatment interruption: coupling the whole-body imaging of the CD4 pool and of the immune system activation | WELBPE06 | Poster Exhibition |
A17 | Evolution of neutralizing antibodies in HIV-1 subtype C infection | WEPDA0101 | Poster Discussion Abstract |
A54 | HLA-B*58:02-specific benefit of MRKAd5 Gag/Pol/Nef vaccine in an African population | WEPDA0102 | Poster Discussion Abstract |
A2 | HIV-1 subtype C is significantly more infectious than other subtypes | WEPDA0103 | Poster Discussion Abstract |
A2 | Functional differences in the viral accessory protein Nef between major HIV-1 subtypes | WEPDA0104 | Poster Discussion Abstract |
A21 | Viral clade affects the mechanism of HLA-B27:05-mediated immune control of HIV | WEPDA0105 | Poster Discussion Abstract |
A5 | CXCR4 tropic HIV-1 is a cause of but not a result of CD4+ T cell count depression | WEPEA100 | Poster Exhibition |
A5 | Deciphering the interactions between the V1V2 domain of the HIV-1 envelope protein gp120 and α4ß7 integrin of the host cell | WEPEA101 | Poster Exhibition |
A6 | Investigation of the sequential development of integrase strand transfer inhibitor resistance mutations in HIV | WEPEA102 | Poster Exhibition |
A6 | Use of amplification refractory mutation system PCR assay as a simple and cost-effective tool to detect HIV-1 drug resistance mutations | WEPEA103 | Poster Exhibition |
A6 | Identification of HIV aberrant strains in Cameroon | WEPEA104 | Poster Exhibition |
A6 | Withdrawal of dolutegravir in early phases of HIV-1 infection in tissue culture does not abrogate antiretroviral activity | WEPEA105 | Poster Exhibition |
A7 | Development of an in vitro assay to assess the function of naturally occurring HIV-1 Vpu sequences without codon optimization | WEPEA106 | Poster Exhibition |
A8 | HIV-1 Rev regulates the expression of Tat and viral replication via modulation of NAD(P)H: quinine oxidoreductase 1 (NQO1) | WEPEA107 | Poster Exhibition |
A8 | Analysis of in vivo splice site usage by HIV-1 transcripts through deep sequencing: high diversity of spliced RNA expression patterns and identification of new splice sites | WEPEA108 | Poster Exhibition |
A11 | Decreased interferon signature in HIV-1 viremic controllers | WEPEA109 | Poster Exhibition |
A11 | Differential effects of cell-surface CD4 and tetherin on ADCC mediated by non-neutralizing and broadly neutralizing anti-HIV antibodies: the role of Nef and Vpu | WEPEA110 | Poster Exhibition |
A11 | PKR as a restriction factor during HIV-1 infection counteracted by virus-induced cellular mechanisms | WEPEA111 | Poster Exhibition |
A12 | Comparison of gene expression profile between human and macaque dendritic cells infected with virus carrying or not Vpx-loaded particles and assessment of their pathogenic impact | WEPEA112 | Poster Exhibition |
A13 | A pseudo-glycodendrimer inhibits DC-SIGN-mediated HIV trans-infection and interferes with DC-SIGN signal | WEPEA113 | Poster Exhibition |
A13 | Investigation of which NK cell populations expressing or not NKG2A, KIR2DL3 or KIR3DL1 are activated by autologous HIV-infected CD4 T cells | WEPEA114 | Poster Exhibition |
A13 | Enhanced capacity of NK-cells from carriers of the protective KIR3DS1 homozygous genotype to inhibit HIV replication in autologous infected CD4 T cells | WEPEA115 | Poster Exhibition |
A13 | DNA methylation analysis of natural killer cells during HIV-1 infection | WEPEA116 | Poster Exhibition |
A13 | NK cells expressing self-inhibitory KIR2DL receptors exhibit a reduced capacity to inhibit HIV-1 replication in vitro | WEPEA117 | Poster Exhibition |
A14 | Functional impairments of macrophages derived from HIV-1+ patients are partially reversed after beginning of HAART | WEPEA118 | Poster Exhibition |
A22 | HIV-1-infected patients under suppressive cART present with various patterns of persistent immune activation: the ACTIVIH study | WEPEA119 | Poster Exhibition |
A22 | The different patterns of immune activation in virologic responders are linked to various causal factors | WEPEA120 | Poster Exhibition |
A22 | Elevated levels of circulating nucleosomes in HIV-infected women: cause or consequence of chronic immune activation? | WEPEA121 | Poster Exhibition |
A23 | HIV-infected individuals with suboptimal CD4 restration despite suppressive antiretroviral therapy exhibit altered CD4+ T cell subsets and escalated both CD4+ and CD8+ T cell exhaustion | WEPEA122 | Poster Exhibition |
A23 | HIV-1 group M subtypes display differential rates of CD4 T cell decline | WEPEA123 | Poster Exhibition |
A24 | Flow virometry: envelope heterogeneity on individual HIV-1 virions | WEPEA124 | Poster Exhibition |
A25 | Serum-derived bovine immunoglobulin (SBI)-induced changes in stool microbiota correlate with levels of microbial translocation (MT) and reduced mucosal damage | WEPEA125 | Poster Exhibition |
A25 | Influence of HIV infection and antiretroviral therapy on the immune status and microbial translocation in HIV-infected children in Vietnam | WEPEA126 | Poster Exhibition |
A25 | TLR2 stimulation acts synergistically with acetate stimulation to promote HIV-1 infection of CD4 + T cells | WEPEA127 | Poster Exhibition |
A27 | Ethnicity impacts inflammatory and coagulation profile in HIV patients | WEPEA128 | Poster Exhibition |
A31 | IL18 and ALOX5AP mRNA levels are increased in HIV-infected individuals despite the use of HAART | WEPEA130 | Poster Exhibition |
A32 | Low frequency of HIV rebound after antiretroviral treatment interruption | WEPEA131 | Poster Exhibition |
A32 | Dynamic imaging of intracellular glutathione redox potential of HIV-1 infected macrophages and its exploitation by Mycobacterium tuberculosis through its lipids | WEPEA132 | Poster Exhibition |
A32 | Histone deacetylase inhibitors alter the accumulation of spliced HIV mRNA: implications for virus production | WEPEA133 | Poster Exhibition |
A32 | Purging HIV-1 from latent reservoirs using human methyltransferase inhibitors | WEPEA134 | Poster Exhibition |
A33 | Immunological markers associated with HIV persistence during ART identified by iterated conditional random forests analysis | WEPEA135 | Poster Exhibition |
A33 | Transcriptional profiling identifies RORC and PPARG as two major mechanisms regulating HIV permissiveness in primary Th17 cells | WEPEA136 | Poster Exhibition |
A33 | Modulation of HERV family expression after treatment with HDAC inhibitors | WEPEA137 | Poster Exhibition |
A34 | Distinct HIV genetic populations in effector memory T cells after prolonged therapy | WEPEA138 | Poster Exhibition |
A34 | Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4+ memory T cells | WEPEA139 | Poster Exhibition |
A34 | Quantification and replication competency of HIV-1 following latency disruption in CD4+ T cells | WEPEA140 | Poster Exhibition |
A34 | T cell immunity in testicular tissue of ART-treated HIV-infected subjects: results from the Orchid study | WEPEA141 | Poster Exhibition |
A34 | Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages | WEPEA142 | Poster Exhibition |
A34 | CTLA-4-expressing memory CD4+ T cells are critical contributors to SIV viral persistence | WEPEA143 | Poster Exhibition |
A35 | Defining the unique biomarkers of latently infected T cells | WEPEA144 | Poster Exhibition |
A35 | Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4+ T cell count at 96 weeks ART | WEPEA145 | Poster Exhibition |
A35 | Defective HIV-1 proviruses in the latent reservoir can be transcribed and translated following latency reversal | WEPEA146 | Poster Exhibition |
A35 | HIV-1 transcription is stable during frequent longitudinal sampling in aviremic patients on ART: implications for HIV cure research | WEPEA147 | Poster Exhibition |